Navigation Links
Cytopia Nominates JAK2 Clinical Candidate for Myeloproliferative Disorders
Date:3/17/2008

sed into formal preclinical studies including IND-enabling toxicology studies. This program will lead to the submission of an Investigational New Drug (IND) application with the US Food and Drug Administration(FDA) in the fourth quarter of 2008. The preclinical development program has already been considered by the FDA in pre-IND reviews, including a face-to-face meeting with FDA reviewers last month.

"The accumulated data for CYT387 clearly indicates that this compound has an excellent potency and safety profile for the treatment of patients with MPDs. We are aggressively progressing this compound through formal preclinical studies with the aim of beginning clinical trials by the end of this year," said Mr. Andrew Macdonald, CEO of Cytopia.

About JAK2

The discovery of a specific single activating mutation in the JAK2 enzyme in MPDs in 2005 has focused attention on developing a therapy for these diseases through selective inhibition of JAK2. To successfully address these chronic diseases with a JAK2 inhibitor, the specificity and resultant tolerability profile is a key element of the product profile required for a "best in class" inhibitor.

CYT387 is a specific JAK2 inhibitor with excellent potential for safe and efficacious chronic human dosing. It has been derived from Cytopia's knowledge of basic biology of JAK kinases, a strong structural biology program that has delivered multiple co-crystal structures of JAK2 complexed with inhibitors, and the subsequent development of an extensive chemical library of JAK2 inhibitors through an integrated computational and medicinal chemistry platform.

Cytopia is developing a suite of JAK2 inhibitors for multiple indications including the treatment of certain cancers, particularly lymphomas and solid tumors where JAK2 has been shown to be up-regulated, and for cardiovascular diseases such as pulmonary hypertension.

About Cytopia

Cytopia Ltd is an Australian biotechnology company
'/>"/>

SOURCE Cytopia Limited
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Pharmacopeia Nominates Novel Chemokine Receptor Antagonist for Development
2. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
3. Baxter Presents Latest Clinical Trial Results of GAMMAGARD LIQUID Administered Subcutaneously
4. Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
5. Raven Announces Initiation of a RAV12 Phase 2 Clinical Trial in Metastatic Pancreatic Cancer
6. Northern California Foot and Ankle Center Santa Rosa Enrolling Patients With Chronic Diabetic Foot Ulcers for Matrix Clinical Research Trial
7. ADVENTRX to Present CoFactor Phase 2 Breast Cancer Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
8. FDA Accepts Investigational New Drug Application for ARI-2243 and a First in Man Clinical Trial Set to Begin During the First Half of 2008
9. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
10. New Clinical Studies Presented at the 14th World Congress of Anesthesiology Demonstrate Masimo Advancements in Patient Care
11. Ception Therapeutics Initiates Phase II/III Clinical Trial for Its Lead Product Reslizumab in Eosinophilic Esophagitis (EE) in Children
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... Aug. 1, 2014 Dyadic International, Inc. ("Dyadic") ... proprietary technologies are used to develop, manufacture and sell ... biopharmaceutical and industrial enzyme industries, announced today that it ... ended June 30, 2014 after market close on Thursday, ... that day at 5:00 p.m. Eastern Time to discuss ...
(Date:7/31/2014)... 1, 2014 Cipla ... heute bekannt, vor kurzem für OneDose ReadyfusOR™ ... nach chirurgischen Eingriffen eine kommerzielle Zusammenarbeit begonnen ... Union und weiterer europäischer Länder abdeckt. Cipla ... Ropivacain gefüllte OneDose ReadyfusOR später in diesem ...
(Date:7/31/2014)... STAAR Surgical Company (NASDAQ: STAA ) a ... delivery systems for the eye today reported revenue for ... million, a 10% increase over $18.2 million reported for ... basis, revenues grew 11% during the second quarter of ... effect of foreign currency exchange reduced sales by $0.1 ...
Breaking Medicine Technology:Dyadic International To Announce Second Quarter 2014 Financial Results And Host Conference Call On Thursday, August 14, 2014 2Dyadic International To Announce Second Quarter 2014 Financial Results And Host Conference Call On Thursday, August 14, 2014 3Cipla und BioQuiddity geben EU-Geschäftspartnerschaft für OneDose-ReadyfusOR zur Schmerzbehandlung nach chirurgischen Eingriffen bekannt 2Cipla und BioQuiddity geben EU-Geschäftspartnerschaft für OneDose-ReadyfusOR zur Schmerzbehandlung nach chirurgischen Eingriffen bekannt 3STAAR Surgical Reports 10% Second Quarter Revenue Growth 2STAAR Surgical Reports 10% Second Quarter Revenue Growth 3STAAR Surgical Reports 10% Second Quarter Revenue Growth 4STAAR Surgical Reports 10% Second Quarter Revenue Growth 5STAAR Surgical Reports 10% Second Quarter Revenue Growth 6STAAR Surgical Reports 10% Second Quarter Revenue Growth 7STAAR Surgical Reports 10% Second Quarter Revenue Growth 8STAAR Surgical Reports 10% Second Quarter Revenue Growth 9STAAR Surgical Reports 10% Second Quarter Revenue Growth 10STAAR Surgical Reports 10% Second Quarter Revenue Growth 11STAAR Surgical Reports 10% Second Quarter Revenue Growth 12STAAR Surgical Reports 10% Second Quarter Revenue Growth 13STAAR Surgical Reports 10% Second Quarter Revenue Growth 14STAAR Surgical Reports 10% Second Quarter Revenue Growth 15STAAR Surgical Reports 10% Second Quarter Revenue Growth 16STAAR Surgical Reports 10% Second Quarter Revenue Growth 17STAAR Surgical Reports 10% Second Quarter Revenue Growth 18STAAR Surgical Reports 10% Second Quarter Revenue Growth 19STAAR Surgical Reports 10% Second Quarter Revenue Growth 20STAAR Surgical Reports 10% Second Quarter Revenue Growth 21STAAR Surgical Reports 10% Second Quarter Revenue Growth 22STAAR Surgical Reports 10% Second Quarter Revenue Growth 23STAAR Surgical Reports 10% Second Quarter Revenue Growth 24STAAR Surgical Reports 10% Second Quarter Revenue Growth 25STAAR Surgical Reports 10% Second Quarter Revenue Growth 26STAAR Surgical Reports 10% Second Quarter Revenue Growth 27STAAR Surgical Reports 10% Second Quarter Revenue Growth 28STAAR Surgical Reports 10% Second Quarter Revenue Growth 29STAAR Surgical Reports 10% Second Quarter Revenue Growth 30STAAR Surgical Reports 10% Second Quarter Revenue Growth 31
... FARMINGDALE, N.Y., Nov. 2, 2011 Misonix, Inc. ... company that designs, manufactures, and markets innovative therapeutic ... cosmetic surgery, neurosurgery, laparoscopic surgery and other surgical ... Ultrasonic Bone Cutting System and the SonaStar® Ultrasonic ...
... 2011 Perrigo Company (Nasdaq: PRGO ; TASE) ... Drug Administration (FDA) a New Drug Application (NDA) for testosterone ... the owner of the Reference Listed Drug of its filing. ... the United States District Court for the District of New ...
Cached Medicine Technology:Misonix Announces its Exhibition at the European Association of Neurosurgical Societies 2Misonix Announces its Exhibition at the European Association of Neurosurgical Societies 3Perrigo Confirms Filing for Testosterone Gel 1.0% and Announcement of Patent Infringement Lawsuit by Abbott 2
(Date:8/2/2014)... Seattle, Wa (PRWEB) August 02, 2014 According ... Vkool.com, this is a comprehensive dating guide for women. The ... attract the man they want easily. The book also teaches ... commitment issues. , Vkool reveals in its review that ...     Chapter 1 – What’s Your Relationship Story? , ...
(Date:8/2/2014)... Lakewood Park Apartment Homes , located ... side, has undertaken a project that promises to help ... sense, while improving the “green” appearance of its already ... announced that Lakewood Park is currently preparing garden plots ... about being able to offer this opportunity to our ...
(Date:8/2/2014)... 02, 2014 When the Black Hat conventioneers ... this year, one thing can be always counted on, plenty ... as fear, uncertainty and doubt. The run-up has already ... article published by Reuters on July 31st about how ... or keyboard to successfully infect a system with malware, completely ...
(Date:8/1/2014)... 2014 Cannabis use among young people has ... to 17 having used marijuana at least once and 17 ... “Say ‘No’ to Drugs, Say ‘Yes to Life,’ volunteers from ... youth this summer with factual information about drugs, to help ... Hamburg “Say ‘No’ to Drugs, Say ‘Yes’ to Life,” volunteers ...
(Date:8/1/2014)... brain plays a central role in regulating appetite and ... in the brain,s control of food intake and body ... process has been unclear. A new study ... that PPARγ activity in a type of neuron known ... response to high-fat diet. Sabrina Diano and colleagues ...
Breaking Medicine News(10 mins):Health News:Girl Gets Ring System Review Exposes Jonathan Green's Dating Guide For Women – Vkool.com 2Health News:Girl Gets Ring System Review Exposes Jonathan Green's Dating Guide For Women – Vkool.com 3Health News:Lexington’s Lakewood Park Apartments Getting Into Gardening 2Health News:Black Hat USA 2014 Will Again Stress Need for Security Basics with Glimpse of What May Lie Ahead 2Health News:Black Hat USA 2014 Will Again Stress Need for Security Basics with Glimpse of What May Lie Ahead 3Health News:Black Hat USA 2014 Will Again Stress Need for Security Basics with Glimpse of What May Lie Ahead 4Health News:Black Hat USA 2014 Will Again Stress Need for Security Basics with Glimpse of What May Lie Ahead 5Health News:Addressing a Serious Issue Affecting German Teens 2
... committee Sunday said medicines sold in shops would indicate ... 2. ,The decision was taken in a meeting ... of chemicals, fertilizers and steel. The members were discussing ... members decided that the 354 drugs in the national ...
... is where the Codex Alimentarius Commission’s role is crucial. If ... uphill task to maintain standards in taste and safety. ... to the European community. This is indeed a combined worthy ... Agriculture Organization of the United Nations. ,They are ...
... The government has planned to alter citeria for jobless benefit ... illness under //reforms being unveiled this week. ,Work and ... off benefit and into work following the publishing of his ... the personal capability assessment which is used to decide whether ...
... Recently an UCLA study by a team of researchers ... carotid atheromas formation in patients //at a higher risk ... link may be due to blockages containing calcium in ... carotid artery. ,These blockages, or atheromas, contain ...
... the disease strides ahead with greater determination from obscurity to ... why is the pandemic// outpacing us, or are countries acting ... million people and affected another 40 million worldwide? ... York for the review meeting to the United Nations General ...
... consider Medical Council of India seniority on appointment in ... ,Talking to reporters here Association General Secretary, ... about 34,000 doctors are unemployed in India in which ... is recruiting doctors for government health services, the government ...
Cached Medicine News:Health News:AIDS: Why the pandemic outpaces us 2Health News:AIDS: Why the pandemic outpaces us 3
... has been designed for use with Bioneer's ... can handle 96 samples (Plasmid DNA, Genomic ... and purification. While conventional kits use centrifugal ... BioVac 96 Vacuum Manifold uses vacuum pressure ...
Plastic Tray Type Vacuum Manifold...
... manifold is designed to efficiently process ... holds one deep well plate and ... are drawn through the wells ... microplates. The base holds and ...
QIAvac 96 is designed for efficient processing of QIAGEN 96-well plates....
Medicine Products: